Top 20 life sciences deals of 2025 point to a hotter M&A market
PharmaShots’ new Top 20 Life Sciences Deals of 2025 report puts a fine point on a year when biopharma dealmaking came back in force. Using DealForma data, the ranking captures the largest partnerships and transactions announced in 2025, with many of the highest-value deals centered on oncology, obesity, and technology-enabled drug development. (linkedin.com)
That fits the broader market backdrop. DealForma reported that global healthcare and life sciences M&A reached 585 deals in 2025, totaling $269.3 billion including contingent payments, versus 466 deals and $140.8 billion in 2024. Average upfront cash and equity also climbed to $1.4 billion, up from $764 million a year earlier, suggesting the rebound wasn’t just driven by a handful of outliers. (dealforma.com)
Among the headline transactions in the PharmaShots ranking were BioNTech’s June 2, 2025 collaboration with Bristol Myers Squibb around the PD-L1/VEGF-A bispecific BNT327, valued at more than $11 billion including milestones, and Takeda’s October 21, 2025 partnership with Innovent covering oncology assets IBI363 and IBI343, worth up to about $11.4 billion. Roche’s March 12, 2025 agreement with Zealand Pharma to co-develop and co-commercialize petrelintide for overweight and obesity also stood out, with total potential value of up to $5.3 billion. Pfizer’s May 2025 ex-China licensing deal with 3SBio for SSGJ-707, a PD-1/VEGF bispecific antibody, added another major oncology bet, with potential value above $6 billion. (news.bms.com)
The pattern is notable. Several of the biggest deals were not traditional full-company acquisitions, but risk-sharing collaborations, licensing arrangements, and milestone-heavy structures. That suggests large drugmakers still want access to late-stage or clinically differentiated assets, while preserving some flexibility on execution and payout timing. Deloitte described 2025 as a year in which pharma pursued “larger, more strategic transactions” and shifted toward more de-risked assets in competitive therapeutic areas. (deloitte.com)
Industry commentary points in the same direction. DealForma’s 2025 review highlighted five especially visible transactions, including Pfizer’s acquisition of Metsera, Merck’s acquisitions of Verona Pharma and Cidara Therapeutics, Sanofi’s acquisition of Blueprint Medicines, and Thermo Fisher Scientific’s purchase of Clario Holdings. In other words, the year’s upper tier combined classic M&A with large platform and product partnerships, reflecting a market that rewarded near-commercial or strategically important assets. (dealforma.com)
Why it matters: For veterinary professionals, the direct read-through is less about a single pet health product and more about the operating environment around animal health innovation. When human life sciences capital shifts toward obesity, oncology, diagnostics, and AI-enabled discovery, those priorities can influence adjacent sectors through shared manufacturing partners, CRO capacity, software tools, investor appetite, and translational science. It can also affect how quickly crossover technologies, including biologics platforms and data-driven drug discovery tools, become available to animal health companies and veterinary diagnostics players. That’s an inference, but it’s grounded in the concentration of 2025 deal value in biopharma, diagnostics, and software-enabled platforms. (dealforma.com)
There’s also a practical business lesson here for veterinary leaders and industry watchers: buyers paid up for assets with clearer differentiation, later-stage data, or strategic fit. Smaller companies, including those in animal health, may read that as a sign that platform stories alone are not enough without sharper clinical, regulatory, or commercial proof points. At the same time, the prominence of AI-linked and cross-border licensing deals suggests partners are still willing to place large bets when the science, geography, and structure line up. (linkedin.com)
What to watch: In 2026, watch for whether the 2025 rebound in life sciences dealmaking broadens beyond marquee human biopharma transactions into animal health partnerships, diagnostics consolidation, and AI-driven R&D deals, especially as companies look for de-risked assets and more efficient development models. (dealforma.com)